Gemtuzumab Ozogamicin the conjugate represents a novel advance in the management of relapsed myeloblastic disease, mainly severe myeloblastic disease (AML). This agent joins a humanized protein directed at the target https://bookmark-template.com/story28591288/this-antibody-drug-the-conjugate-a-comprehensive-analysis